Who is sponsoring NCT03904667?

NCT03904667 is sponsored by Zhujiang Hospital.

What drugs are being tested in NCT03904667?

Interventions in NCT03904667: Watson on oncology surgery decision evaluation.

What condition does NCT03904667 study?

NCT03904667 studies Liver Resection.

Is NCT03904667 still recruiting?

NCT03904667 is currently status unknown. Last updated 5 April 2019.

Last reviewed 2019-04-05 · How we verify

NCT03904667

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Application of Watson for Oncology in Hepatocellular Carcinoma Surgery

Status unknown Last updated 5 April 2019

What this trial tests

trial testing Watson on oncology surgery decision evaluation in Liver Resection in 150 participants. Status unknown.

Timeline

1 January 2017

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Zhujiang Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 January 2017
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Watson on oncology surgery decision evaluation

Conditions studied

Liver Resection — all drugs for Liver Resection →

Sponsor

Zhujiang Hospital

Who can join

Adults 18 to 80, any sex, with Liver Resection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to evaluate the surgical decisions of Watson artificial intelligence in patients with hepatocellular carcinoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Resection

Currently open trials in the same condition.

NCT06638502 — Safety of HRX215 in Patients After Minor and Major Liver Resection · Phase 1, PHASE2 · recruiting
NCT07385521 — The Use of Artificial Intelligence for the Prediction of Recurrence After Resection of Colorectal Liver Metastases · recruiting
NCT06905015 — Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver · NA · recruiting

Other Zhujiang Hospital trials

Trials by the same sponsor.

NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03904667 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
Last refreshed: 5 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03904667.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing